The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s minimal residual disease testing market report forecasts the minimal residual disease testing market size to grow to $2.32 Billion by 2027, with a CAGR (compound annual growth rate) of more than 13%.

Learn More On The Minimal Residual Disease Testing Market Report 2023 – https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-testing-global-market-report

Minimal Residual Disease Testing Market Size Forecast
The global minimal residual disease testing market is expected to grow from $1.22 billion in 2022 to $1.41 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global minimal residual disease testing market size is expected to reach $2.32 billion in 2027 at a CAGR of 13.3%.

North America held the largest minimal residual disease testing market share.

Key Minimal Residual Disease Testing Market Driver ­– Increase In The Prevalence Of Cancer
For example, according to reports released by the World Health Organisation (WHO), a Swiss-based health institution, cancer will be the leading cause of death worldwide in February 2022. According to the World Cancer Fund Research International, a non-profit organisation located in the United Kingdom dedicated to cancer prevention, there will be 18,094,716 million new cases of cancer worldwide in 2020. Furthermore, nearly 10 million individuals died from cancer worldwide in 2020, accounting for nearly one in every six deaths. As a result, the growing occurrence of cancer is propelling the minimal residual disease testing market forward.

Request for A Sample Of The Global Minimal Residual Disease Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp

Key Minimal Residual Disease Testing Market Trend – Product Innovations
To maintain their market position, major firms in the minimal residual disease testing market are developing new products. Twist Bioscience, a synthetic biology and genomics business based in the United States, for example, introduced the Twist MRD Panel in 2022 to accelerate research and development in minimal residual disease (MRD) identification in cancer screening. The Twist MRD Panel is a gene panel that may be customised to identify very low amounts of residual cancer cells in a patient’s blood. The Twist MRD Panel is designed to be very adaptable and adjustable, allowing it to be integrated into a standard next-generation sequencing (NGS) workflow and detect minimum residual disease (MRD) in just five days.

Minimal Residual Disease Testing Market Segment
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic and Research Institutes, Other End Users

Minimal Residual Disease Testing Market Major Players and Strategies
Major players in the minimal residual disease testing market are Natera Inc., Guardant Health, Laboratory Corporation of America Holdings, QIAGEN N.V, F. Hoffmann-La Roche Ltd, Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC., Veracyte Inc., Cergentis B.V, Mdxhealth, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers, and PerkinElmer Inc.

GRAIL was acquired for $8 billion by Illumina Inc., a biotechnology business based in the United States, in August 2021. With this transaction, Illumina Inc. increased patient access to a life-saving multi-cancer early-detection test and expanded its worldwide health services. GRAIL is a biotechnology business established in the United States that uses next-generation sequencing testing technologies and minimal residual disease testing to diagnose cancer at an early stage.

The Minimal Residual Disease Testing Global Market Report 2023 covers regional data on minimal residual disease testing market size, minimal residual disease testing market trends and drivers, opportunities, strategies, and minimal residual disease testing market competitor analysis. The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Minimal residual disease testing is a highly sensitive test for detecting cancer cells that may linger in the patient’s body after treatment. It is used to assess the efficacy of cancer treatment and to guide future treatment choices.

View More Reports Related To The Minimal Residual Disease Testing Market –
Minimal Invasive Surgery Devices Global Market Report 2023
Minimally Invasive Surgical Instruments Global Market Report 2023
Minimally Invasive And Non Invasive Product And Service Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: